MedTrace Logo

A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

NCT00812799 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2010-04-30

No results posted yet for this study

Summary

This study will be performed to determine the long-term efficacy of 19.000 BU Oralgen grass pollen administered daily in patients with grass pollen related allergic rhinoconjunctivitis.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

DRUG

Oralgen

19.000 BU daily

OTHER

placebo control

placebo control

Sponsors & Collaborators

  • Artu Biologicals

    lead INDUSTRY

Principal Investigators

  • Folkert Roossien · Artu-Biologicals Europe B.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-08-31
Completion
2011-12-31

Countries

  • Belgium
  • France
  • Germany
  • Netherlands
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812799 on ClinicalTrials.gov